#Tchia litman therapy how to

Some of these include the use of tyrosine kinase inhibitors such as Imatinib for chronic myelogenous leukaemia harbouring the BCR-ABL translocation (Annunziata et al, 2020), BRAF/MEK inhibitors for BRAF mutated cancers (Zaman et al, 2019), HER2-targeted therapies in breast cancer (Wang & Xu, 2019), and inhibitors of EGFR or ALK kinases in lung adenocarcinomas driven by EGFR mutation or ALK fusions (Bernicker et al, 2019). There have been a number of notable successes in the development of targeted therapy.

#Tchia litman therapy how to

However, a remaining challenge is how to use this information to identify therapeutic targets and predictive biomarkers to guide clinical decision-making about whether a particular drug is likely to be effective for the treatment of a specific patient’s disease. Rapidly developing sequencing technology, in conjunction with advances in computational analysis, has culminated in the genomic and transcriptomic characterization of individual patients’ tumours, bringing the possibility of precision-medicine to the clinic. Interactions between tumour cells and the cells and growth factors within its surrounding environment, such as stromal cells, blood vessels and infiltrating inflammatory cells.Drug therapy directed at a specific gene product or pathway, as opposed to chemotherapy, which is less specific and targets all proliferating cells.This refers to the different clones (that harbour distinct genomic aberrations) present in different areas of a tumour and that appeared at different time points in disease progression.A marker (e.g., genetic abnormality or protein) that can be used to predict the response of a tumour to a specific therapy.

Patient-derived tumour xenografts that are co-treated with the same therapies as the patient to mimic changes that would occur in the patient in order to evaluate response to therapy and changes in clonal heterogeneity.

In cancer biology, this refers to how specific genetic alterations produce changes in the properties of tumour cells. The association between a specific genotype (i.e., genetic alteration) and the resulting phenotype (i.e., observable characteristic).